Dublin, Oct. 12, 2020 (GLOBE NEWSWIRE) -- The "Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030" report has been added to ResearchAndMarkets.com's offering.
The 'Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030' report provides a detailed study on the current market landscape and future potential of the companies having the capabilities to manufacture radiopharmaceuticals.
According to an article published by World Nuclear Association in May 2020, more than 10,000 hospitals worldwide claim to be using radioisotopes for various medical procedures; interestingly, of the aforementioned applications, 90% were reported to be related to disease diagnosis Typically, diagnostic tests, involving radiopharmaceuticals, are performed using highly specialized imaging solutions, such as single photon emission computed tomography (SPECT) and positron emission tomography (PET).
It is worth highlighting that around 40 million diagnostic procedures, involving the use of the radioisotope Tc-99m alone, are conducted worldwide annually. Further, the introduction of the concept of theranostics, which involves the use of a single active ingredient for both diagnostic and therapeutic purposes, has opened up a new dimension of applications for nuclear medicine.
Over the years, medical research teams across the world have gradually tapped into the vast potential of radiopharmaceuticals and nuclear medicines. In fact, the technology that is now used in this field is reported to have witnessed significant evolution, in terms of technological sophistication.
As a result, the demand for such specialized chemicals has grown at an exponential rate. However, the development and production of radiopharmaceuticals is inherently complex, and requires specialized facilities and operational expertise.lucrative opportunities to the contract service providers that are engaged in this domain.
Scope Of the Report
A detailed assessment of the current market landscape with respect to the players (industry and non-industry) involved in manufacturing radiopharmaceuticals. It features information on the year of establishment, company size, purpose of production (fulfilling in-house requirements / for contract services), location of headquarters, location of manufacturing facilities, scale of production, applications of radiopharmaceuticals (in diagnosis, therapeutics and theranostics), type of diagnostic radiopharmaceuticals (PET and SPECT), type of therapeutic radiopharmaceuticals (alpha emitters, beta emitters and others), target therapeutic area (cardiology, oncology, neurology, thyroid and others) and services offered.
An insightful four-dimensional comparison of the radiopharmaceutical manufacturers, based on supplier power (year of establishment), product portfolio (number of isotopes being manufactured for various applications targeting different therapeutic areas) of the manufacturer, scale at which they manufacture their respective products and company size.
Tabulated profiles of key industry players based in North America, Europe and Asia-Pacific (shortlisted based on the company size of the players), featuring a brief overview of the company, a list of products and manufacturing facilities, recent developments and an informed future outlook.
An analysis of recent partnerships and collaborations inked in this domain since 2017, based on several parameters, such as the type of partnership, year of partnership, type of radioisotope involved, therapeutic area mentioned in the agreement, application of the radioisotope mentioned in the agreement, and a schematic representation showcasing the players that have forged the maximum number of alliances. Furthermore, we have provided a world map representation of the deals inked in this field, highlighting those that have been established within and across different continents.
A detailed discussion on the supply chain model of medical isotope Mo-99 (Tc-99m), highlighting the main steps of the supply chain, from irradiation of uranium targets in nuclear research reactors to the administration of Tc-99m to patients. Along with this, it describes the structure of the industry and product market at each step.
Key Questions Answered
Who are the leading industry and non-industry players engaged in the nuclear medicine and radiopharmaceutical manufacturing market?
For which application and disease indications are the radiopharmaceuticals being manufactured?
What are the various type of radionuclides being manufactured for the formulation of radiopharmaceuticals?
What is the relative competitiveness of manufacturers involved in the nuclear medicine and radiopharmaceutical manufacturing?
Which partnership models are commonly adopted by the radiopharmaceutical manufacturers in this industry?
What is the supply chain process for medical isotope Mo-99 / Tc-99m?
What are the key factors that are likely to influence the evolution of the nuclear medicine and radiopharmaceutical manufacturing market?
How is the current and future market opportunity likely to be distributed across key market segments?
3D Imaging Drug Design and Development
ABX advanced biochemical compounds
Advanced Accelerator Applications
Advanced Nuclear Medicine Ingredients
Ahmanson Translational Imaging Division
ASAN Medical Center
Australian Nuclear Science and Technology Organisation
Biomedical Research Imaging Center, UNC School of Medicine
Blue Earth Diagnostics
Board of Radiation and Isotope Technology
Canadian Nuclear Isotope Council
Cancer Targeted Technology
Center for Molecular and Genomic Imaging, UC Davis
Center for Neurosciences, The Feinstein Institute
Center for Radiochemistry Research, OHSU Knight Cardiovascular Institute
Center for Systems Imaging Core, Emory University
Centre for Advanced Imaging, The University of Queensland
Centre for In Vivo Imaging, Newcastle University
Centre for Probe Development and Commercialization
Chengdu Gaotong Isotope
Chengdu New Radiomedicine Technology
China Isotope & Radiation Corporation
Clinical Imaging Research Centre, National University of Singapore
Crump Cyclotron and Radiochemistry Technology Center,University of California
Cyclotron & Radiochemistry Facility, Stanford University School of Medicine
Cyclotron and Radiochemistry Facility, Citigroup Biomedical Imaging Center of Weill Cornell Medicine
Cyclotron and Radiochemistry Facility, UT Southwestern Medical Center
Cyclotron and Radiochemistry Laboratories, Keck School of Medicine of USC
Cyclotron and Radiopharmaceutical Core, Houston Methodist Research Institute
Cyclotron and Radiopharmaceuticals Department, King Faisal Specialist Hospital and Research Centre
Cyclotron Facility, University of Chicago
Cyclotron Radiochemistry Facility, MD Anderson Cancer Center
Department of Molecular and Medical Pharmacology, University of California
Department of Nuclear Medicine and PET, Liverpool Hospital
Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine
Department of Nuclear Medicine, School of Health Sciences, University of Ioannina
Department of Radiology & Biomedical Imaging, University of California
Department of Radiology, The University of Alabama at Birmingham
Department of Radiology, University of Colorado
Department of Radioplogy, Penn Medicine, University of Pennsylvania
Eckert & Ziegler
FUJIFILM Toyama Chemical
GE Hitachi Nuclear Energy
Global Medical Solutions
Global Morpho Pharma
Heidelberg University Hospital
Huntsman Cancer Institute Center for Quantitative Cancer Imaging, Univeristy of Utah Health
Imaging Facilities, The University of Manchester
Institut National des Radioelements
Institute for Energy Technology
Institute of Applied Radiopharmacy of Barcelona
Institute of Isotopes (IZOTOP)
Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf
IRE ELiT- Radiopharmaceuticals
Isotopia Molecular Imaging
ITM Isotopen Technologien Munchen
Korea Insititute of Radiological & Medical Sciences
Kresge Cyclotron/PET Facility, Department of Radiology, University of Michigan
Lantheus Medical Imaging
Life Molecular Imaging
Mallinckrodt Institute of Radiology, PET Nuclear Pharmacy and Cyclotron Facility, Washington University
Mallinckrodt Nuclear Imaging
Map Medical Technologies
McMaster University Cyclotron Facility
Memorial Sloan Kettering Cancer Center
Molecular Imaging Institute (M2i)
National Centre for Nuclear Research Radioisotope Centre (POLATOM)
Ningbo Junan Pharmaceuticals Technology
Nordal Cyclotron & PET Radiochemistry, Lawson Health Research Institute
Nuclear and Energy Research Institute
Nuclear Medicine and Molecular Imaging, University of Groningen
Nuclear Medicine/Biomedical Imaging Research Core, Brigham and Women's Hospital
Nuclear Research Institute Rez
Ontario Power Generation
PET Center, Columbia University
PET Core, Gordan Center for Medical Imaging, Harvard Medical School
PET Pharm Biotech
PET Radiochemistry and Radiopharmacy, University of Oxford
PET Research Core, Renaissance School of Medicine, Stony Brook University
PET Research Facility, Wake Forest School of Medicine
PET Research Radiochemistry, University of Ottawa
Radboud University Medical Center
Radiochemistry & Molecular Imaging Probes Core Facility, Memorial Sloan Kettering Cancer Center
Radiochemistry Core, University of Virginia
Radiochemistry Core, Vanderbilt University Institute of Imaging Science
Radiochemistry Facility, Loma Linda University
Radiochemistry Unit, University of Helsinki
Radiopharmaceutical Core Facility, Case Western Reserve University
Radiopharmazeutische Wissenschaften, Division of Nuclear Medicine at the Medical University of Vienna
Research Imaging Institute, University of Teaxs Health Science Center
Rosatom State Atomic Energy Corporation
Saskatchewan Centre for Cyclotron Sciences
Societatea Nationala Nuclearelectrica
The McConnell Brain Imaging Centre, University of McGrill
Thunder Bay Cyclotron and Radiochemistry Laboratories, Lakehead University
Turku PET Centre
United Imaging Healthcare
University of Melbourne
University of Missouri
University of Washington Radiochemistry Resources
USC Molecular Imaging Center, University of Southern California
Wolfson Brain Imaging Centre, University of Cambridge
For more information about this report visit https://www.researchandmarkets.com/r/a8i3ry
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900